Haemodynamic effects of riociguat in inoperable/recurrent chronic thromboembolic pulmonary hypertension.

ABSTRACT:

Objective

We compared the haemodynamic effects of riociguat in patients with inoperable chronic thromboembolic pulmonary hypertension (CTEPH) or persistent/recurrent CTEPH after pulmonary endarterectomy in the Chronic Thromboembolic Pulmonary Hypertension Soluble Guanylate Cyclase-Stimulator Trial 1 study.

Methods

Patients with inoperable or persistent/recurrent CTEPH (n=261; mean± SD age 59±14 years; 66% women) were randomised to riociguat (up to 2.5 mg three times daily) or placebo. Haemodynamic parameters were assessed at baseline and week 16.

Results

Riociguat decreased pulmonary vascular resistance (PVR) in inoperable (n=189; least-squares mean difference: -285 dyn s/cm⁵ (95% CI -357 to -213); p<0.0001) and persistent/recurrent (n=72; -131 dyn s/cm

SUBMITTER: Kim NH 

PROVIDER: S-EPMC5529957 | biostudies-literature | 2017 Apr

REPOSITORIES: biostudies-literature